Biocardia announces first canadian clinical site for cardiamp cell therapy heart failure trial

Sunnyvale, calif., aug. 01, 2022 (globe newswire) -- biocardia®, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of ottawa heart institute, the first canadian clinical investigational site for the cardiamp® cell therapy heart failure trial.
BCDA Ratings Summary
BCDA Quant Ranking